GLA
NBIX icon

Great Lakes Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Great Lakes Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$487K Sell
3,693
-59
-2% -$7.83K ﹤0.01% 601
2025
Q4 		$532K Buy
3,752
+147
+4% +$21.3K ﹤0.01% 599
2025
Q3 		$506K Buy
3,605
+84
+2% +$11.4K ﹤0.01% 617
2025
Q2 		$443K Sell
3,521
-28,485
-89% -$3.27M ﹤0.01% 634
2025
Q1 		$3.54M Buy
32,006
+27,431
+600% +$3.47M 0.03% 341
2024
Q4 		$624K Sell
4,575
-5,832
-56% -$721K 0.01% 630
2024
Q3 		$1.2M Sell
10,407
-100,871
-91% -$13.8M 0.01% 561
2024
Q2 		$15.3M Sell
111,278
-4,339
-4% -$595K 0.14% 149
2024
Q1 		$15.9M Sell
115,617
-47,868
-29% -$6.54M 0.14% 154
2023
Q4 		$21.5M Buy
163,485
+1,528
+0.9% +$176K 0.21% 122
2023
Q3 		$18.2M Buy
161,957
+121,592
+301% +$12.8M 0.17% 129
2023
Q2 		$3.81M Sell
40,365
-43,349
-52% -$4.24M 0.04% 380
2023
Q1 		$8.47M Buy
83,714
+41,488
+98% +$4.32M 0.08% 248
2022
Q4 		$5.04M Sell
42,226
-878
-2% -$103K 0.29% 124
2022
Q3 		$4.58M Buy
+43,104
New +$4.37M 0.1% 225
2018
Q4 		– Sell
-75,389
Closed -$9.27M – 606
2018
Q3 		$9.27M Buy
+75,389
New +$8.55M 0.2% 113

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Lakes Advisors's NBIX Position: Q1 2026 in Review

Great Lakes Advisors reduced its Neurocrine Biosciences (NBIX) stake by 1.6% in Q1 2026, selling an estimated $7.83K and leaving 3,693 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

Great Lakes Advisors first reported a position in NBIX in Q3 2018 and has held it in 16 quarters since. The position peaked at $21.5M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Great Lakes Advisors held 3,693 shares of Neurocrine Biosciences worth $487K as of Q1 2026.
  • Great Lakes Advisors sold 59 Neurocrine Biosciences shares in Q1 2026, an estimated $7.83K.
  • Neurocrine Biosciences made up ﹤0.01% of Great Lakes Advisors's portfolio in Q1 2026, its #601 holding.
  • Great Lakes Advisors first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 16 quarters since.
  • Great Lakes Advisors's Neurocrine Biosciences position peaked at $21.5M in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Great Lakes Advisors's 13F filing for Q1 2026, filed 12 May 2026.